Transasia Bio-Medicals Ltd.

  A chronic metabolic disease, diabetes now affects more than 77 mn Indians, a number which is expected to grow to 134 mn by 2045. Diabetes and its types Diabetes occurs either when the pancreas doesn’t produce enough insulin to regulate blood glucose or when the body cannot effectively use the insulin it produces. The main types of diabetes are: Type 1: Previously known as Insulin Dependent Diabetes or Juvenile Diabetes, it is caused due to body’s malfunction to produce insulin. Type 2: This is caused due to insulin resistance, a condition in which cells fail to use insulin properly. This form was previously known as non-insulin dependent diabetes or adult onset diabetes. Besides this there is a third type, the Gestational diabetes that occurs in pregnant women, who develop a high blood glucose level without previous history of diabetes. Global prevalence of diabetes According to the International Diabetes Federation (IDF), there are 537 mn adults now living with diabetes and its gl

  Thrombosis or blood clotting can be a clinically silent condition, proving to be critical without any warning signs. However, blood clots can be prevented and treated, if detected in time. On World  Thrombosis Day, Transasia Bio-Medicals sheds some light on the prevalence of VTE and its detection by a simple blood test such as D Dimer.  Blood clots - the first line of defense or a cause of concern? Blood clotting or coagulation is the body’s defense tactic against bleeding. In the case of an injury, the clotting system is activated to ‘plug’ the injury site and prevent excess blood loss. Once healed, the body breaks down the clot. In certain instances, the blood clot may fail to dissolve after an injury, or clots may form inappropriately, within a blood vessel, preventing normal flow. This process is called thrombosis. Know the different types Broadly speaking there are two main types - venous and arterial, depending on where the clot occurs. Arterial thrombosis can result in hear

  All ISO standards are reviewed and revised regularly to make sure they remain relevant to the marketplace. ISO 13485:2016 responds to the latest QMS practices, reflecting the evolution in medical device technology and changes in regulatory requirements and expectations. Transasia is the first Indian IVD Company to receive the ICMED 13485 quality certificate in 2018 for indigenously manufactured medical devices.   ISO 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, is an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. Designed to be used by organizations throughout the lifecycle of a medical device, from initial conception to production and post-production, it includes final decommission and disposal. It also covers aspects such as storage, distribution, installation and servicing, and the provision of associated services. En

  The pandemic has led to a paradigm shift in the diagnostic industry. Direct-to-home testing and focus on preventive healthcare are disrupting the industry to become more patient-centric in the future.      Until a few years back, the role of clinical laboratory was to provide vital information on disease diagnosis aiding medical professionals in management through appropriate interventions. However, advancements in IT enabled diagnostics techniques, for both equipment and testing, have led to greater efficiencies.  Building better testing capabilities- Advancements in product technology and the need for convenient sampling is leading to a paradigm shift for less invasive tests that rely on saliva and dried blood spots. Sampling of saliva is beneficial for the healthcare professionals too, as it spares them the risk of being exposed to the infected sample during collection. Similarly, dried blood spots technique is gaining preference for neonatal tests.    As technology continues to

  Viral hepatitis is a growing concern in India and is recently equated as a threat comparable to the “big three” communicable diseases – HIV/AIDS, Malaria, and Tuberculosis. While we continue our fight against COVID-19, let’s not forget that, hepatitis too can’t wait!   Hepatitis, referred to as inflammation of the liver, can be caused due to alcohol abuse, medications, and certain medical conditions. However, hepatitis is often caused by a virus; and the most common types viral hepatitis are hepatitis A, hepatitis B and hepatitis C. Viral hepatitis can lead to severe liver disease including hepatocellular cancer. A global health concern, hepatitis-related illness, claims one life, every 30 seconds!   Viral hepatitis is a cause for major healthcare burden in India and is recently equated as a threat comparable to the “big three” communicable diseases – HIV/AIDS, Malaria, and Tuberculosis. The Government of India launched a new National Viral Hepatitis Control Program (NVHCP) on World

  Urinalysis is one of the most frequently performed clinical investigations carried out in both inpatient and outpatient settings, due to its high information content and accessibility. Over the past two decades, technological advancement has led to the development of modern fully automated urine sediment analyzers, that make it possible to standardize results and increase laboratory productivity. Time and again, routine urinalysis has proved its clinical utility for screening, diagnosing and monitoring of renal, urological and metabolic conditions. It also plays an important role in the evaluation of liver function and several urological malignancies. Urinary tract infections (UTIs) are extremely common worldwide. In addition to detecting leukocytes and nitrites, urine microscopy identifies bacteria. These findings are crucial to the treatment process. In the current pandemic, urinalysis is useful in unveiling potential renal impairment due to COVID-19. Technological advancements A

  Transasia Bio-Medicals Ltd., India’s Leading IVD Company has stepped up its efforts to augment the capacity of various state governments to provide timely medical support to COVID-19 patients.  As India fights the second wave of the pandemic, Transasia has swiftly arranged to provide 200 BiPAP machines along with 40 cell counters and 30 coagulation analyzers, worth more than Rs. 2.25 crores which have been distributed to various COVID-dedicated hospitals across India. On receiving a request from the Tamil Nadu government, apart from 25 BiPAP machines that provide oxygen support, Transasia also donated 32 units of H 360, three-part differential hematology analyzer, and 5 and 3 units of H 560 and Elite 580 respectively, five-part differential hematology analyzer s. These equipments aid  in monitoring disease severity in COVID patients. Similarly, in Delhi, Transasia has provided 30 BiPAP machines along with 30 units of ECL 105, coagulation analyzers. ECL 105 will help Doctors in